ACTUATE THERAPEUTICS, INC.

Actuate Therapeutics, Inc.

Biotechnology • Healthcare • Fort Worth, TX, United States • ACTU (NGM)

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.

817 887 8455 1751 River Run, Fort Worth, TX 76107, United States

Stock Performance (90 Days)

Data through Dec 30, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Yahoo Finance • Dec 24
Can Actuate Therapeutics' Elraglusib Overcome The Hurdles Of GSK-3ß Inhibition? - RTTNews
RTTNews • Dec 29
Actuate Therapeutics Announces Closing of $17.25 Million - GlobeNewswire
GlobeNewswire • Sep 11
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma - Yahoo Finance
Yahoo Finance • Dec 15
HC Wainwright & Co. Reiterates Actuate Therapeutics (ACTU) Buy Recommendation - Nasdaq
Nasdaq • Nov 19

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has ACTUATE THERAPEUTICS, INC. had layoffs?
No layoff events have been recorded for ACTUATE THERAPEUTICS, INC. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does ACTUATE THERAPEUTICS, INC. have?
ACTUATE THERAPEUTICS, INC. has approximately 10 employees.
What industry is ACTUATE THERAPEUTICS, INC. in?
ACTUATE THERAPEUTICS, INC. operates in the Biotechnology industry, within the Healthcare sector.
Is ACTUATE THERAPEUTICS, INC. a publicly traded company?
Yes, ACTUATE THERAPEUTICS, INC. is publicly traded under the ticker symbol ACTU on the NGM. The company has a market capitalization of approximately $0.14 billion.
Where is ACTUATE THERAPEUTICS, INC. headquartered?
ACTUATE THERAPEUTICS, INC. is headquartered in Fort Worth, TX, United States at 1751 River Run, Fort Worth, TX 76107, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.